HilleVax, Inc. (NASDAQ:HLVX) Given Consensus Rating of “Hold” by Analysts

HilleVax, Inc. (NASDAQ:HLVX) has received an average rating of “Hold” from the six research firms that are covering the stock, Marketbeat reports. Six equities research analysts have rated the stock with a hold rating. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $9.20.

A number of research analysts have commented on the company. Leerink Partnrs downgraded HilleVax from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 9th. Leerink Partners downgraded HilleVax from an “outperform” rating to a “market perform” rating and lowered their target price for the company from $28.00 to $2.00 in a research note on Tuesday, July 9th. Guggenheim downgraded HilleVax from a “buy” rating to a “neutral” rating in a research note on Monday, July 8th. HC Wainwright restated a “neutral” rating and issued a $2.00 target price on shares of HilleVax in a research note on Monday, August 12th. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating and set a $5.00 price target (down previously from $24.00) on shares of HilleVax in a research note on Monday, July 8th.

Institutional Trading of HilleVax

Several large investors have recently made changes to their positions in the stock. Catalys Pacific LLC bought a new stake in HilleVax during the 4th quarter valued at approximately $21,009,000. Franklin Resources Inc. boosted its stake in HilleVax by 4.1% during the 4th quarter. Franklin Resources Inc. now owns 1,846,396 shares of the company’s stock valued at $29,635,000 after purchasing an additional 71,938 shares during the period. Swiss National Bank boosted its stake in HilleVax by 22.4% during the 4th quarter. Swiss National Bank now owns 38,200 shares of the company’s stock valued at $613,000 after purchasing an additional 7,000 shares during the period. Tidal Investments LLC bought a new stake in HilleVax during the 1st quarter valued at approximately $207,000. Finally, TD Asset Management Inc boosted its stake in HilleVax by 53.9% during the 2nd quarter. TD Asset Management Inc now owns 54,236 shares of the company’s stock valued at $784,000 after purchasing an additional 19,000 shares during the period. Institutional investors own 86.42% of the company’s stock.

HilleVax Trading Down 0.6 %

Shares of HLVX stock opened at $1.80 on Monday. HilleVax has a 1-year low of $1.55 and a 1-year high of $20.22. The company has a market capitalization of $89.50 million, a price-to-earnings ratio of -0.55 and a beta of 0.81. The stock’s fifty day simple moving average is $1.80 and its 200-day simple moving average is $9.59.

HilleVax (NASDAQ:HLVX) last issued its earnings results on Thursday, August 8th. The company reported ($0.83) EPS for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.10). On average, sell-side analysts predict that HilleVax will post -2.47 EPS for the current year.

HilleVax Company Profile

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.